A survivin peptide-based vaccine, SurVaxM, has also demonstrated safety, tolerability, and immunogenic effects in human patients with malignant gliomas and metastatic neuroendocrine tumours (NETs) in numerous clinical trials.14, 15, 16, 17 However, the immunogenicity of this vaccine may be limited and only to certain HLA haplotypes, such as HLA-A∗02, HLA-A∗03, and HLA-A∗24 due to the nature of its design.14 The gene discussed is BIRC5; the disease is malignant glioma.